The following would suggest that testing for CH before T-cell therapy is undertaken is part of the answer.
Also, the fact that the incidence of cancer increases with age, suggests that CH could be more prevalent in older people. And, we already know that the first iterations of any new technology such as Car-T are "clunky" and that combination therapies are also the answer.
I reckon rejuvenating stem cells the same way that our CellPryme makes the immune cells' phenotype younger could be one way to go to combat this issue the CH issue!
Whether CellPryme (news) will solve my age-related issues after all this time is another matter. Time will tell... but I wish FGS that Steve would tell!
